Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular and fully automated diagnostics platform Idylla™.
The Idylla™ GeneFusion Assay will include a highly multiplexed panel of established and emerging biomarkers, and will be the first FFPE1 RNA2-based assay on the Idylla™ platform. The Idylla™ GeneFusion Assay is expected to bring results in approx. 3 hours, with less than 2 minutes hands-on time. The VLAIO grant is intended to support the development of the GeneFusion Assay on the Idylla™ platform, and to support related research studies on different sample and tumor tissue types, including on lung cancer tissue.
Lung cancer is the most common cause of cancer-related deaths worldwide (27%) with 1.7 million deaths annually3. Clinical non-small cell lung cancer (NSCLC) guidelines4 recommend testing for amongst others EGFR mutations5. Today, gene fusions represent an increasingly important biomarker test category6. Although detected in a small portion of NSCLCs, testing for these gene fusions is important for the identification of patients who may benefit from different fusion gene targeted therapies, which show high response rates and long disease control upon treatment7. Current testing methods however are cumbersome because different technologies8 are needed to test all required biomarkers. Additionally, sample quantity and quality to perform all these tests are commonly suboptimal. Due to these complexities, time to results can be delayed, which can lead to inappropriate treatment decisions.
We are very pleased to receive this VLAIO grant and support from the Flemish government for highly innovative projects such as our GeneFusion Assay project. In the area of lung cancer testing, there is a clear unmet diagnostic need for comprehensive and fast molecular testing solutions that are compatible with a limited amount of sample. Together with the existing Idylla™ EGFR Mutation Test (CE-IVD), a key test in our lung cancer menu, the Idylla™ GeneFusion Assay (RUO9) is expected to offer our customers-laboratories a comprehensive testing solution for molecular biomarkers in this area, without the need for different instruments, and covering the majority of clinical guideline-recommended biomarkers–Herman Verrelst, Chief Executive Officer of Biocartis
Biocartis expects to launch its Idylla™ GeneFusion Assay as a Research Use Only (RUO) assay in Q1 2021. Validation and release of an IVD version for use in NSCLC is also anticipated.
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next-generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest-growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer.
